Genprex (NASDAQ:GNPX) Stock Price Up 0.9% – Time to Buy?

Genprex (NASDAQ:GNPX)’s stock price was up 0.9% on Monday . The company traded as high as $3.65 and last traded at $3.48. Approximately 116,474 shares were traded during mid-day trading, an increase of 143% from the average daily volume of 47,903 shares. The stock had previously closed at $3.45.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Genprex in a research note on Friday, July 17th. One investment analyst has rated the stock with a Sell rating, According to data from MarketBeat, Genprex has an average rating of “Sell”.

Genprex Trading Up 0.9%

The firm’s 50 day moving average price is $5.01 and its two-hundred day moving average price is $17.13. The company has a market capitalization of $2.85 million, a price-to-earnings ratio of -0.03 and a beta of -0.94.

Genprex (NASDAQ:GNPX) last issued its quarterly earnings data on Friday, August 14th. The company reported ($9.40) earnings per share (EPS) for the quarter.

Institutional Investors Weigh In On Genprex

An institutional investor recently bought a new stake in Genprex stock. Mayflower Financial Advisors LLC purchased a new stake in Genprex (NASDAQ:GNPX) in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm purchased 20,000 shares of the company’s stock, valued at approximately $36,000. Mayflower Financial Advisors LLC owned 0.22% of Genprex at the end of the most recent quarter. Institutional investors own 14.05% of the company’s stock.

Genprex Company Profile

Genprex, Inc is a clinical-stage biotechnology company focused on developing gene therapies for cancer and other serious diseases. The company’s technology is designed to deliver therapeutic genes into cells using a nonviral delivery system, with the goal of restoring tumor-suppressor activity or producing other disease-fighting effects.

Genprex’s lead product candidate is REQORSA® Immunogene Therapy (quaratusugene ozeplasmid), an investigational gene therapy being developed primarily for non-small cell lung cancer.